KZR-8445
KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2377734-91-1
- 화학식: C49H61BrF6N8O8
- 분자량:1083.95
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
IL-2 |
IL-1β |
IL-6 |
IL-23 |
KZR-8445 (0.1-10000 nM; 24 h) directly targets Sec61α to potently inhibit secretion of IL-2-GLuc and TNFα-GLuc in HEK293 Flp-In T-REx cells expressing WT Sec61α, with an IC50 of ~100 nM[1].
KZR-8445 (24 h) inhibits secretion of GLuc reporters fused to HER3, prolactin, PD1, TNFα, and IL-2 signal peptides in HEK293 Flp-In T-REx cells with IC50 values ranging from 32 nM to 1068 nM[1].
KZR-8445 potently inhibits secretion of Sec61-dependent pro-inflammatory cytokines with submicromolar IC50 values in activated human PBMCs, while sparing cell viability at concentrations up to 20 µM[1].
KZR-8445 (0.01-10 µM; 2 h) inhibits SARS-CoV-2 replication and spike protein biogenesis in Vero E6 cells while maintaining cell viability above 50% at concentrations up to 10 µM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 7-8 weeks old, rheumatoid arthritis induced via intravenous anti-type II collagen antibody cocktail on day 0 + intraperitoneal LPS (HY-D1056) on day 3)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.v.; weekly/weekly; 2 weeks
-
Result:Blocked disease progression with a statistically significant effect at 10 and 20 mg/kg thrice weekly.
Significantly blocked disease progression at 20 mg/kg weekly.
Showed no significant toxicity, with body weight changes comparable to or greater than vehicle-treated mice across all treatment groups.
Chemical Information
-
CAS No. 2377734-91-1
-
분자량 1083.95
-
화학식 C49H61BrF6N8O8
-
SMILES
BrC(C=C1)=CC=C1CN2C3=CC=CC=C3C(C[C@@H]4N(C([C@@H](NC([C@@H](N(C([C@@H](NC([C@H](OC([C@@H](N(C([C@@H](NC4=O)CC(C)C)=O)C)C)=O)CCC#N)=O)CC(F)(F)F)=O)C)CC(C)C)=O)CC(F)(F)F)=O)C)=C2
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz